Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684641 · ClinicalTrials.gov registry record · Phase 1
CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04684641 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 8 participants.
The verdict
NCT04684641, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the safety profile of phage therapy in this patient population.
Interventions
- OTHER Placebo
- DRUG Standard Dose YPT-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2023-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04684641
The ClinicalTrials.gov registry entry for NCT04684641 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04684641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04684641 about?
NCT04684641 is a clinical study titled "CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)". This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the safety profile of phage therapy in this patient population.
What is the current status of trial NCT04684641?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-03-29. Estimated completion is 2023-06-22.
What interventions are being tested in trial NCT04684641?
The interventions under investigation include: Placebo (OTHER), Standard Dose YPT-01 (DRUG).
Who is sponsoring clinical trial NCT04684641?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.